✨ Free AI Report
Ainos, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Ainos, Inc.
Company Research

Ainos, Inc.: Business Overview, Financials & Competitive Analysis

Ainos, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage dual-platform AI and biotech innovator with first-mover advantage in smelltech but requiring multiple value inflection points for profitable scale. Ainos operates in cutting-edge smelltech and immune therapeutics with novel technology platforms and demonstrated revenue growth (499% YoY in fiscal year 2026), but faces significant challenges including micro-cap valuation (~$14-16M).

What is Ainos, Inc.'s industry? Ainos, Inc. (ainos.com) operates in In-Vitro Diagnostics. AskCyborg classifies Ainos, Inc. under In-Vitro Diagnostics in its company registry.

Ainos, Inc. is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics, with its smelltech platform powered by AI Nose and smell language model (SLM) that digitizes scent into Smell ID, a m...

4/ 10Mixed

Cyborg Score thesis

Early-stage dual-platform AI and biotech innovator with first-mover advantage in smelltech but requiring multiple value...

Read the full analyst-debate transcript →
Industry In-Vitro Diagnostics
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 12, 2026
AI-Verified Research
30+ Page Report

Get the Latest Ainos, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Ainos, Inc.

AskCyborg analysts argue the bull and bear cases for Ainos, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Ainos, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Ainos, Inc. Overview

Pro stress-test →

Ainos, Inc. is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics, with its smelltech platform powered by AI Nose and smell language model (SLM) that digitizes scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases, with active clinical programs including HIV-related oral warts, primary Sjögren's syndrome, and feline chronic gingivostomatitis.

Strategic Profile

Pro stress-test →

The company provides its platforms for semiconductor manufacturing, robotics, and smart manufacturing industries, as well as senior care and women's health sectors. Ainos operates as a micro-cap public company with emerging technology in artificial olfaction and biotech therapeutics, though it remains pre-profitability with significant execution risk.

Competitive Landscape

Pro stress-test →

Ainos competes in nascent smelltech/electronic olfaction space with limited direct competitors, though it faces indirect competition from traditional point-of-care diagnostics providers and from broader AI/robotics sensing companies. In immune therapeutics, VELDONA competes against conventional interferon therapies and emerging immunomodulatory biologics. The company's differentiation rests on novel AI-driven scent digitization technology and low-dose formulation approach, but remains largely unproven at scale.

Industry Context

Ainos, Inc. operates in In-Vitro Diagnostics.

Key facts

Founded: 1984 (as Amarillo Biosciences); rebranded 2021 · Headquarters: Houston, Texas, US · Employees: 41 · Revenue: Not disclosed (449% YoY growth FY2026) · Market cap: $14-16M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Ainos, Inc..

  • Ainos released its 2026 mid-year shareholder letter reporting 499% year-over-year revenue growth during fiscal year 2026
  • Ainos, Inc. is a subsidiary of Taiwan Carbon Nano Technology Corporation, providing strategic backing and Asian market access
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • June 2026National Taiwan University research program announced to study AI Nose applications
  • Q2 2026VASRO GmbH published research report discussing Ainos' AI Nose expansion
  • +1 moreTrack every material event for Ainos, Inc. as it happens. Explore monitoring →
Get alerted when Ainos, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Interferon therapeuticsAlternative interferon-based therapeutics for immunomodulation→AryballeAI-driven digital olfaction platform using silicon photonics and biosensors for scent detection and analysis→AromajoinScent controllable technology and digital olfaction platform for fragmentrance digitalization→OsmoDigital olfaction startup providing scent sensing and analysis technology→

Compare Ainos, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Ainos, Inc. operates in In-Vitro Diagnostics. See how the rest of the sector scores on the Cyborg framework.

Browse In-Vitro Diagnostics research →
NEW · MCP server

Ask your AI assistant about Ainos, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Ainos, Inc. and its top competitor on Cyborg Score”
“What did Ainos, Inc. do this quarter?”
“Is Ainos, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Ainos, Inc. do?+
Ainos, Inc. is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics, with its smelltech platform powered by AI Nose and smell language model (SLM) that digitizes scent into Smell ID, a m...
What is Ainos, Inc.'s Cyborg Score?+
Ainos, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Ainos, Inc.'s main competitors?+
Named competitors include Interferon therapeutics, Aryballe, Aromajoin, Osmo. The full competitive landscape is in the AskCyborg report.
How can I get the full Ainos, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Ainos, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Ainos, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More In-Vitro Diagnostics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7DiaSorin S.p.A.7Shenzhen New Industries Biomedical Engineering Co., Ltd.4Biosynex SA